The FDA on November 15, 2023, approved AUGTYRO® (Repotrectinib) for locally advanced or metastatic ROS1-positive Non-Small Cell Lung Cancer (NSCLC). AUGTYRO® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement